Pheast Therapeutics has treated the first subject in a multi-centre Phase I trial for the anti-cluster of differentiation 24 (CD24) macrophage checkpoint blocker PHST001, aimed at treating advanced ...

To grow, cancer tumors must hijack the immune system for their needs. One of the main tricks that most tumors use is to ...

New methods for deriving macrophages from induced pluripotent stem cells are easier to scale and provide more clinically ...

Cardiovascular disease (CVD) is the leading cause of death and disease burden worldwide. Macrophages are important components ...

Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors.

REDWOOD CITY, CA, USA I April 14, 2025 I Pheast Therapeutics, a private biotechnology company developing novel therapies to unleash the power of macrophages ...

Researchers discovered that EBV infection triggers macrophage pyroptosis—a form of inflammatory cell death—by accelerating glycolysis, a key metabolic pathway. This cascade of events worsens ...

The polarization response of macrophages seeded on titanium materials is influenced by multiple factors, and artificial intelligence can assist in extracting the key features of implant materials for ...

This study provides proof-of-principle data for the use of trained immunity to modulate macrophage interactions with tumours. The study makes a valuable contribution to the field of trained immunity.

Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal ...